Krystal Biotech Gets Positive CHMP Opinion For Vyjuvek To Treat Dystrophic Epidermolysis Bullosa
28/2 14:23
(RTTNews) - Krystal Biotech, Inc. (KRYS) Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bull...